What is the recommended work‑up and treatment for a patient with anxiety and panic attacks that are resistant to adequate SSRI therapy, to rule out and manage pheochromocytoma?

Pheochromocytoma Screening in Treatment-Resistant Anxiety

Screen for pheochromocytoma in patients with anxiety and panic attacks resistant to adequate SSRI therapy by measuring plasma or 24-hour urinary metanephrines, particularly when imaging shows an adrenal mass >10 HU on non-contrast CT or when patients exhibit signs of catecholamine excess such as paroxysmal hypertension, palpitations, sweating, or headaches. 1

Clinical Recognition and When to Suspect Pheochromocytoma

Pheochromocytoma can masquerade as primary psychiatric illness for years, with anxiety being the fourth most common presenting symptom after the classic triad of headache, palpitations, and sweating. 2

• Case evidence demonstrates diagnostic delays of 13-15 years when pheochromocytoma presents primarily with anxiety and panic disorder, with complete resolution of panic attacks after surgical resection. 2, 3

• Key clinical clues distinguishing pheochromocytoma from primary anxiety include:

  • Paroxysmal hypertension with tachycardia and flushing during episodes 4
  • Treatment resistance to standard psychiatric medications including SSRIs 2
  • Associated symptoms of sweating, headaches, and palpitations occurring in discrete episodes 5
  • Metabolic abnormalities such as hypokalemia or metabolic alkalosis 4

Diagnostic Work-Up Algorithm

Initial Screening

All patients with treatment-resistant anxiety should undergo focused history and physical examination specifically assessing for signs of adrenergic excess including episodic hypertension, tachycardia, diaphoresis, and headaches. 1

Biochemical Testing

The guideline-recommended approach depends on imaging characteristics:

• For patients WITHOUT adrenal imaging or with masses >10 HU on non-contrast CT: Screen with plasma or 24-hour urinary metanephrines and normetanephrines. 1

• For patients with confirmed adrenocortical adenomas (<10 HU on unenhanced CT) and NO signs of adrenergic excess: Screening for pheochromocytoma is NOT recommended. 1

Imaging Protocol

• First-line imaging: Non-contrast CT to characterize any adrenal mass, with Hounsfield units <10 indicating benign adenoma. 1

• Second-line imaging: If mass remains indeterminate on non-contrast CT, proceed with washout CT or chemical-shift MRI. 1

• Avoid routine adrenal mass biopsy in the work-up of suspected pheochromocytoma. 1

Additional Hormonal Screening

Since psychiatric presentations can overlap with other endocrine disorders:

• Screen ALL patients with adrenal incidentalomas for autonomous cortisol secretion using 1 mg dexamethasone suppression testing, as Cushing syndrome commonly presents with panic attacks and can mimic pheochromocytoma. 1, 4

• Screen patients with hypertension and/or hypokalemia for primary aldosteronism with aldosterone-to-renin ratio. 1

Treatment Approach

Surgical Management

Adrenalectomy should be performed for confirmed pheochromocytomas, with minimally-invasive surgery when feasible. 1

• Preoperative preparation is essential: Catecholamine blockade with phenoxybenzamine and metyrosine ameliorates symptoms and prevents hypertensive crisis during surgery. 5

• Psychiatric symptoms typically resolve completely after surgical resection, allowing discontinuation of psychiatric medications. 2

Multidisciplinary Review

Maintain a low threshold for multidisciplinary review involving endocrinologists, surgeons, and radiologists when imaging is not consistent with a benign lesion or there is evidence of hormone hypersecretion. 1

Critical Pitfalls to Avoid

• Do not dismiss long-standing psychiatric symptoms as purely functional without excluding medical causes, as pheochromocytoma can remain undiagnosed for over a decade. 2, 3

• Recognize that pheochromocytoma is present in approximately 0.3% of patients with secondary hypertension and autopsy series reveal many are never clinically suspected, potentially leading to fatal complications. 5

• Do not rely solely on the classic triad of headache, palpitations, and sweating, as some patients present with atypical or predominantly psychiatric manifestations. 6

• Avoid screening for pheochromocytoma in patients with unequivocal adrenocortical adenomas (<10 HU) without signs of catecholamine excess, as this represents unnecessary testing. 1